Tirzepatide emerges a groundbreaking treatment agent for individuals battling type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://chiaramnln406586.digitollblog.com/40500062/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist